Table 1.
Correlation between CPSF3 expression and clinicopathological characteristics in TCGA and ICGC HCC cohorts.
| Variables | TCGA (n = 344) | ICGC (n = 232) | ||||
|---|---|---|---|---|---|---|
| Low risk group |
High risk group |
P-value | Low risk group |
High risk group |
P-value | |
| Age (years) | 0.209 | 0.424 | ||||
| < 60 | 149 | 22 | 34 | 11 | ||
| ≥ 60 | 158 | 15 | 130 | 57 | ||
| Sex | 0.494 | 0.773 | ||||
| Male | 207 | 27 | 120 | 51 | ||
| Female | 100 | 10 | 44 | 17 | ||
| Prior- Malignancy | - | 0.604 | ||||
| No | - | - | 144 | 58 | ||
| Yes | - | - | 20 | 10 | ||
| Histologic grade | 0.279 | - | ||||
| G1/2 | 194 | 20 | - | - | ||
| G3/4 | 113 | 17 | - | - | ||
|
TNM stage |
0.012 | 0.001 | ||||
| I/II | 233 | 21 | 112 | 30 | ||
| III/IV | 74 | 16 | 52 | 38 | ||
| Survival status | < 0.001 | < 0.001 | ||||
| Alive | 216 | 14 | 144 | 45 | ||
| Dead | 91 | 23 | 20 | 23 | ||
Bold values represent P-values less than 0.05.
Notes: TCGA: The Cancer Genome Atlas, HCC: hepatocellular carcinoma, AJCC: American Joint Committee on Cancer.